Activin and Inhibin

HS014 TFA is a potent and selective melanocortin-4 (MC4) receptor antagonist, with K i s of 3.16, 108, 54.4 and 694 nM for human MC4, MC1, MC3 and MC5 receptors respectively. HS014 TFA increases food intake in free-feeding

HS024 is a selective MC4 receptor antagonist, with K i s of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake.Appearance:SolidIC50&amp: Target:MC4RBiological Activity:HS024 is a selective MC4 receptor

HS024 is a selective MC4 receptor antagonist, with K i s of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake.Appearance:SolidIC50&amp: Target:MC4RBiological Activity:HS024 is a selective MC4 receptor

HS024 is a selective MC4 receptor antagonist, with K i s of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake.Appearance:SolidIC50&amp: Target:MC4RBiological Activity:HS024 is a selective MC4 receptor

HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC 50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes

HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC 50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes

HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC 50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes

HSD-016 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with IC 50 values of 11, 1 and 8 nM against human, mouse and rat 11β-HSD1, respectively. HSD-016 can be used for type 2 diabetes

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC 50 of 1.3 nM. Antihyperglycemic activitiesIn VitroHSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC 50 of 1.3 nM. Antihyperglycemic activitiesIn VitroHSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC 50 of 1.3 nM. Antihyperglycemic activitiesIn VitroHSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of

hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC 50 of &lt:0.05 nM. hSMG-1 inhibitor 11e shows &gt:900-fold selectivity over mTOR (IC 50 of 45 nM), PI3Kα/γ (IC 50 s of 61 nM and 92 nM) and CDK1/CDK2 (IC 50 s of 32 μM